Bicycle Therapeutics (BCYC) Expected to Announce Earnings on Tuesday

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $5.47 million for the quarter.

Bicycle Therapeutics Price Performance

BCYC traded up $0.06 on Friday, reaching $12.55. The company's stock had a trading volume of 146,137 shares, compared to its average volume of 321,785. The stock has a market cap of $866.58 million, a price-to-earnings ratio of -3.81 and a beta of 0.93. Bicycle Therapeutics has a 1 year low of $11.14 and a 1 year high of $28.67. The business's 50 day moving average is $14.31 and its 200 day moving average is $20.15.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and set a $33.00 target price on shares of Bicycle Therapeutics in a report on Monday, January 13th. B. Riley reduced their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $35.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Finally, JMP Securities dropped their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $33.25.

Insider Activity at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 9,038 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 985,397 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average price of $13.76 per share, for a total transaction of $13,559,062.72. Following the completion of the transaction, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. This trade represents a 11.52 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 27,677 shares of company stock worth $392,413 in the last three months. 8.50% of the stock is owned by company insiders.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.